Sai Parenterals' CEO, Anil KK said the company's acquisition of a prescription-based business in India is expected to create significant long-term value, with meaningful contributions likely over the next three years. Talking to NDTV Profit in KYC show he added that investments in the Australian entity should support margin expansion, while the integration process has already been completed successfully. The company remains focused on increasing investments in research and development and has retained key management talent across levels to ensure business continuity and drive future growth.